Which has higher earnings & valuation, LNSR or IRIX?

IRIDEX has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than IRIDEX, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.21 -$34.28M -$0.58 N/A IRIDEX $52.67M 0.30 -$4.44M -$0.19 N/A

Is LNSR or IRIX more profitable?

LENSAR has a net margin of 50.94% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% IRIDEX -6.23% N/A -11.16%

Does the media prefer LNSR or IRIX?

In the previous week, IRIDEX had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for IRIDEX and 1 mentions for LENSAR. LENSAR's average media sentiment score of 0.95 beat IRIDEX's score of 0.00 indicating that LENSAR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IRIDEX 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IRIX or DXR?

IRIDEX currently has a consensus target price of $3.00, indicating a potential upside of 227.83%. Given IRIDEX's higher probable upside, equities research analysts plainly believe IRIDEX is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, IRIX or DXR?

Daxor has lower revenue, but higher earnings than IRIDEX. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IRIDEX $52.67M 0.30 -$4.44M -$0.19 N/A Daxor N/A N/A N/A N/A N/A

Is IRIX or DXR more profitable?

Daxor has a net margin of 0.00% compared to IRIDEX's net margin of -6.23%. Company Net Margins Return on Equity Return on Assets IRIDEX -6.23% N/A -11.16% Daxor N/A N/A N/A

Does the media favor IRIX or DXR?

In the previous week, IRIDEX had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for IRIDEX and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat IRIDEX's score of 0.00 indicating that Daxor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IRIDEX 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IRIX or SNWV more profitable?

Sanuwave Health has a net margin of 35.96% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat Sanuwave Health's return on equity. Company Net Margins Return on Equity Return on Assets IRIDEX -6.23% N/A -11.16% Sanuwave Health 35.96% -450.56% 44.87%

Does the media favor IRIX or SNWV?

In the previous week, Sanuwave Health had 1 more articles in the media than IRIDEX. MarketBeat recorded 3 mentions for Sanuwave Health and 2 mentions for IRIDEX. IRIDEX's average media sentiment score of 0.00 equaled Sanuwave Health'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IRIDEX 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanuwave Health 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, LUNG or IRIX?

IRIDEX has lower revenue, but higher earnings than Pulmonx. IRIDEX is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.56 -$54M -$1.30 N/A IRIDEX $52.67M 0.30 -$4.44M -$0.19 N/A

Is LUNG or IRIX more profitable?

IRIDEX has a net margin of -6.23% compared to Pulmonx's net margin of -60.09%. IRIDEX's return on equity of 0.00% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% IRIDEX -6.23% N/A -11.16%

Does the media refer more to LUNG or IRIX?

In the previous week, Pulmonx had 2 more articles in the media than IRIDEX. MarketBeat recorded 4 mentions for Pulmonx and 2 mentions for IRIDEX. Pulmonx's average media sentiment score of 0.49 beat IRIDEX's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IRIDEX 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NYXH or IRIX?

IRIDEX has higher revenue and earnings than Nyxoah. IRIDEX is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 5.23 -$101.92M -$2.48 N/A IRIDEX $52.67M 0.30 -$4.44M -$0.19 N/A

Is NYXH or IRIX more profitable?

IRIDEX has a net margin of -6.23% compared to Nyxoah's net margin of -543.21%. IRIDEX's return on equity of 0.00% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% IRIDEX -6.23% N/A -11.16%

IRIDEX (IRIX) Competitors

$0.92 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$0.92 +0.01 (+0.64%)

As of 04:04 PM Eastern

Compare

IRIX vs. LNSR, DXR, SNWV, LUNG, and NYXH

Should you buy IRIDEX stock or one of its competitors? MarketBeat compares IRIDEX with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IRIDEX include LENSAR (LNSR), Daxor (DXR), Sanuwave Health (SNWV), Pulmonx (LUNG), and Nyxoah (NYXH). These companies are all part of the "medical equipment" industry.

How does IRIDEX compare to LENSAR?

LENSAR (NASDAQ:LNSR) and IRIDEX (NASDAQ:IRIX) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

LENSAR has a net margin of 50.94% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
IRIDEX	-6.23%	N/A	-11.16%

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 8.6% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IRIDEX has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than IRIDEX, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.21	-$34.28M	-$0.58	N/A
IRIDEX	$52.67M	0.30	-$4.44M	-$0.19	N/A

LENSAR has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, IRIDEX has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

In the previous week, IRIDEX had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for IRIDEX and 1 mentions for LENSAR. LENSAR's average media sentiment score of 0.95 beat IRIDEX's score of 0.00 indicating that LENSAR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IRIDEX	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENSAR presently has a consensus target price of $10.00, suggesting a potential upside of 73.91%. IRIDEX has a consensus target price of $3.00, suggesting a potential upside of 227.83%. Given IRIDEX's higher possible upside, analysts clearly believe IRIDEX is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

LENSAR beats IRIDEX on 10 of the 16 factors compared between the two stocks.

How does IRIDEX compare to Daxor?

IRIDEX (NASDAQ:IRIX) and Daxor (NASDAQ:DXR) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

20.1% of IRIDEX shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 8.6% of IRIDEX shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IRIDEX has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, IRIDEX had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for IRIDEX and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat IRIDEX's score of 0.00 indicating that Daxor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IRIDEX	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

IRIDEX currently has a consensus target price of $3.00, indicating a potential upside of 227.83%. Given IRIDEX's higher probable upside, equities research analysts plainly believe IRIDEX is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has a net margin of 0.00% compared to IRIDEX's net margin of -6.23%.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.23%	N/A	-11.16%
Daxor	N/A	N/A	N/A

Daxor has lower revenue, but higher earnings than IRIDEX.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.30	-$4.44M	-$0.19	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

IRIDEX and Daxor tied by winning 5 of the 10 factors compared between the two stocks.

How does IRIDEX compare to Sanuwave Health?

IRIDEX (NASDAQ:IRIX) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Sanuwave Health has lower revenue, but higher earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.30	-$4.44M	-$0.19	N/A
Sanuwave Health	$44.05M	1.16	$11.81M	$0.33	18.03

In the previous week, Sanuwave Health had 1 more articles in the media than IRIDEX. MarketBeat recorded 3 mentions for Sanuwave Health and 2 mentions for IRIDEX. IRIDEX's average media sentiment score of 0.00 equaled Sanuwave Health'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IRIDEX	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanuwave Health	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by insiders. Comparatively, 14.4% of Sanuwave Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IRIDEX has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

IRIDEX currently has a consensus price target of $3.00, indicating a potential upside of 227.83%. Sanuwave Health has a consensus price target of $51.00, indicating a potential upside of 757.14%. Given Sanuwave Health's stronger consensus rating and higher possible upside, analysts clearly believe Sanuwave Health is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Sanuwave Health has a net margin of 35.96% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.23%	N/A	-11.16%
Sanuwave Health	35.96%	-450.56%	44.87%

Summary

Sanuwave Health beats IRIDEX on 13 of the 15 factors compared between the two stocks.

How does IRIDEX compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and IRIDEX (NASDAQ:IRIX) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Pulmonx had 2 more articles in the media than IRIDEX. MarketBeat recorded 4 mentions for Pulmonx and 2 mentions for IRIDEX. Pulmonx's average media sentiment score of 0.49 beat IRIDEX's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IRIDEX	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IRIDEX has lower revenue, but higher earnings than Pulmonx. IRIDEX is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.56	-$54M	-$1.30	N/A
IRIDEX	$52.67M	0.30	-$4.44M	-$0.19	N/A

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 8.6% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pulmonx currently has a consensus target price of $5.58, suggesting a potential upside of 361.43%. IRIDEX has a consensus target price of $3.00, suggesting a potential upside of 227.83%. Given Pulmonx's stronger consensus rating and higher possible upside, research analysts plainly believe Pulmonx is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has a net margin of -6.23% compared to Pulmonx's net margin of -60.09%. IRIDEX's return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
IRIDEX	-6.23%	N/A	-11.16%

Pulmonx has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, IRIDEX has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Summary

Pulmonx beats IRIDEX on 9 of the 16 factors compared between the two stocks.

How does IRIDEX compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and IRIDEX (NASDAQ:IRIX) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, IRIDEX had 2 more articles in the media than Nyxoah. MarketBeat recorded 2 mentions for IRIDEX and 0 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.00 equaled IRIDEX'saverage media sentiment score.

Company	Overall Sentiment
Nyxoah	Neutral
IRIDEX	Neutral

Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, IRIDEX has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Nyxoah presently has a consensus price target of $5.96, suggesting a potential upside of 289.71%. IRIDEX has a consensus price target of $3.00, suggesting a potential upside of 227.83%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts clearly believe Nyxoah is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has a net margin of -6.23% compared to Nyxoah's net margin of -543.21%. IRIDEX's return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
IRIDEX	-6.23%	N/A	-11.16%

20.1% of IRIDEX shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 8.6% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IRIDEX has higher revenue and earnings than Nyxoah. IRIDEX is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.23	-$101.92M	-$2.48	N/A
IRIDEX	$52.67M	0.30	-$4.44M	-$0.19	N/A

Summary

IRIDEX beats Nyxoah on 8 of the 15 factors compared between the two stocks.

Get IRIDEX News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRIX vs. The Competition

Export

Metric	IRIDEX	LASERS Industry	Computer Sector	NASDAQ Exchange
Market Cap	$15.93M	$799.70M	$38.48B	$12.68B
Dividend Yield	N/A	N/A	3.16%	9.42%
P/E Ratio	-4.82	35.45	161.31	21.69
Price / Sales	0.30	141.02	597.35	93.78
Price / Cash	N/A	38.37	46.08	60.45
Price / Book	-15.25	15.31	9.29	6.16
Net Income	-$4.44M	-$16.97M	$1.07B	$331.73M
7 Day Performance	-12.85%	-4.41%	-1.97%	-1.96%
1 Month Performance	-22.45%	-12.70%	-2.86%	-2.49%
1 Year Performance	-33.69%	-25.99%	137.30%	17.21%

IRIDEX Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRIX IRIDEX	1.3687 of 5 stars	$0.92 flat	$3.00 +227.8%	-27.4%	$15.93M	$52.67M	N/A	120	News Coverage Gap Up
LNSR LENSAR	2.5 of 5 stars	$5.79 +0.5%	$10.00 +72.8%	-56.8%	$71.08M	$58.44M	N/A	110	News Coverage
DXR Daxor	2.0893 of 5 stars	$10.84 +1.7%	N/A	+14.5%	$63.18M	N/A	N/A	37	Positive News
SNWV Sanuwave Health	2.5326 of 5 stars	$7.13 -40.4%	$51.00 +615.6%	-84.2%	$61.83M	$44.05M	21.79	40	High Trading Volume
LUNG Pulmonx	3.8334 of 5 stars	$1.46 -1.7%	$5.58 +283.7%	-60.1%	$61.46M	$90.50M	N/A	250	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRIX) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IRIDEX (IRIX) Competitors